The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.

Inclusion Criteria:

• Have symptomatic PAD with intermittent claudication of Fontaine Stage II
• Have an Ankle Brachial Index (ABI) of 0.9 or less

Exclusion Criteria:

• Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m2)
• Have Hemoglobin A1c (HbA1c) greater than 10%
• Have walking ability limited by conditions other than PAD
• Have a planned lower limb surgery or any other surgery affecting walking ability
• Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial
• Had stroke, transient ischemic attack, myocardial infarction, coronary or carotid revascularization, or hospitalization for unstable angina pectoris within 60 days prior to screening
• Have heart failure presently classified as being in New York Heart Association class III - IV

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.